Detalhe da pesquisa
1.
Time-to-Event Analysis of Paclitaxel-Associated Peripheral Neuropathy in Advanced Non-Small-Cell Lung Cancer Highlighting Key Influential Treatment/Patient Factors.
J Pharmacol Exp Ther
; 375(3): 430-438, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-33008871
2.
A phase 1 healthy male volunteer single escalating dose study of the pharmacokinetics and pharmacodynamics of risdiplam (RG7916, RO7034067), a SMN2 splicing modifier.
Br J Clin Pharmacol
; 85(1): 181-193, 2019 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30302786
3.
PKPD modeling of acquired resistance to anti-cancer drug treatment.
J Pharmacokinet Pharmacodyn
; 44(6): 617-630, 2017 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-29090407
4.
A prognostic baseline blood biomarker and tumor growth kinetics integrated model in paclitaxel/platinum treated advanced non-small cell lung cancer patients.
CPT Pharmacometrics Syst Pharmacol
; 12(11): 1714-1725, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-36782356
5.
A model-based approach leveraging in vitro data to support dose selection from the outset: A framework for bispecific antibodies in immuno-oncology.
CPT Pharmacometrics Syst Pharmacol
; 12(11): 1804-1818, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37964753
6.
Novel in Vivo and in Vitro Pharmacokinetic/Pharmacodynamic-Based Human Starting Dose Selection for Glofitamab.
J Pharm Sci
; 111(4): 1208-1218, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-34953862
7.
Preclinical InVivo Data Integrated in a Modeling Network Informs a Refined Clinical Strategy for a CD3 T-Cell Bispecific in Combination with Anti-PD-L1.
AAPS J
; 24(6): 106, 2022 10 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-36207642
8.
Preclinical Characterization of a Next-Generation Brain Permeable, Paradox Breaker BRAF Inhibitor.
Clin Cancer Res
; 28(4): 770-780, 2022 02 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-34782366
9.
Predicting Tumor Killing and T-Cell Activation by T-Cell Bispecific Antibodies as a Function of Target Expression: Combining In Vitro Experiments with Systems Modeling.
Mol Cancer Ther
; 20(2): 357-366, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33298591
10.
Hematopoietic cells as site of first-pass catabolism after subcutaneous dosing and contributors to systemic clearance of a monoclonal antibody in mice.
MAbs
; 10(5): 803-813, 2018 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-29621428
11.
Correction: Preclinical In Vivo Data Integrated in a Modeling Network Informs a Refined Clinical Strategy for a CD3 TCell Bispecific in Combination with AntiPDL1.
AAPS J
; 25(3): 34, 2023 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37002450
12.
Combining Nonclinical Experiments with Translational PKPD Modeling to Differentiate Erlotinib and Gefitinib.
Mol Cancer Ther
; 15(12): 3110-3119, 2016 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-27638857
13.
Translational PK/PD modeling for cardiovascular safety assessment of drug candidates: Methods and examples in drug development.
J Pharmacol Toxicol Methods
; 70(1): 73-85, 2014.
Artigo
em Inglês
| MEDLINE | ID: mdl-24879942
14.
Optimize administration protocol of capecitabine plus docetaxel combination in metastatic breast cancer patients.
Curr Top Med Chem
; 12(15): 1665-8, 2012.
Artigo
em Inglês
| MEDLINE | ID: mdl-22978334
15.
Progress in strategies for dosage regimen individualization.
Curr Top Med Chem
; 12(15): 1669-77, 2012.
Artigo
em Inglês
| MEDLINE | ID: mdl-22978335
16.
DPD-based adaptive dosing of 5-FU in patients with head and neck cancer: impact on treatment efficacy and toxicity.
Cancer Chemother Pharmacol
; 67(1): 49-56, 2011 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-20204365
17.
Cytidine deaminase residual activity in serum is a predictive marker of early severe toxicities in adults after gemcitabine-based chemotherapies.
J Clin Oncol
; 28(1): 160-5, 2010 Jan 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-19933910
18.
Early severe toxicities after capecitabine intake: possible implication of a cytidine deaminase extensive metabolizer profile.
Cancer Chemother Pharmacol
; 63(6): 1177-80, 2009 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-19107485